APOC3 x AGT

Last update 08 May 2025

Basic Info

Related Targets

APOC3AGT

Drugs associated with APOC3 x AGT

STP237G

Target

AGT x APOC3

Mechanism

AGT inhibitors [+1]

Active Org.

Sirnaomics, Inc.

Originator Org.

Sirnaomics, Inc.

Active Indication

Hypertension [+1]

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

100 Clinical Results associated with APOC3 x AGT

100 Translational Medicine associated with APOC3 x AGT

0 Patents (Medical) associated with APOC3 x AGT

Literatures (Medical) associated with APOC3 x AGT

01 Dec 2025·Molecular Biology Reports

Metabolic syndrome and effect of gene polymorphisms: ADIPOQ, AGT, AGTR1, AGTR2, ApoC-III, NR3C1 and GNB3 gene polymorphisms

Article

Author: Oyaci, Yasemin ; Hasanoglu Sayin, Sevde ; Serin, Istemi ; Medetalibeyoglu, Alpay ; Pehlivan, Mustafa ; Senkal, Naci ; Pehlivan, Sacide ; Kose, Murat ; Tukek, Tufan

BACKGROUNDMetabolic syndrome (MetS) is defined as a metabolic dysfunction characterized by the co-occurrence of multiple risk factors. Our study aimed to elucidate the effects of ADIPOQ rs266729, rs17300539, and rs2241766, AGT rs699 and rs4762, AGTR1 rs5186, AGTR2 rs11091046, ApoC-III rs2854116 and rs2854117, NR3C1 rs10052957 and rs41423247, and GNB3 rs5443 gene polymorphisms on MetS.METHODS AND RESULTSA total of 200 patients who met the diagnostic criteria for MetS at the Internal Medicine Outpatient Clinic of Istanbul University, Faculty of Medicine, between 01.08.2022 and 20.05.2023, and 100 healthy controls were included in our study. ADIPOQ rs17300539 GA, AGT rs699 TT, AGTR1 rs5186 AC, and AGTR2 rs11091046 CC genotypes were more frequently observed in patients diagnosed with MetS compared to healthy controls (p < 0.05 for all). MetS patients with AGT rs699 TT genotype had a higher incidence of hypertension compared to individuals with CC/CT genotype of the same polymorphism (p = 0.047). Individuals with ADIPOQ rs17300539 AA/AG and NR3C1 rs41423247 CC genotypes were found to have higher mean waist circumferences compared to others (p < 0.05 for all). Individuals with ADIPOQ rs17300539 AA/AG, NR3C1 rs10052957 GG, and AGT rs4762 GA/AA genotypes exhibited significantly higher incidence of nephropathy. Individuals with ADIPOQ rs17300539 AA/AG and NR3C1 rs10052957 GG genotypes had a significantly higher incidence of retinopathy compared to others.CONCLUSIONSThe study demonstrated that the ADIPOQ rs17300539, AGT rs699, AGTR1 rs5186, and AGTR2 rs11091046 polymorphisms are associated with an increased susceptibility to MetS. Significant results concerning clinical features and complications were also observed. Further research is necessary to elucidate the relationship between susceptibility to MetS, clinical and laboratory characteristics, and epigenetic modifications.

02 Sep 2024·Cardiovascular Research

Advances in nucleic acid-targeted therapies for cardiovascular disease prevention

Review

Author: Steinhagen-Thiessen, Elisabeth ; Volpe, Massimo ; Makhmudova, Umidakhon ; Landmesser, Ulf

AbstractNucleic acid-based therapies are being rapidly developed for prevention and management of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the delivery, safety, and effectiveness of these therapeutics in the past decade. These therapies can also modulate therapeutic targets that cannot be sufficiently addressed using traditional drugs or antibodies. Among the nucleic acid-targeted therapeutics under development for CVD prevention are RNA-targeted approaches, including antisense oligonucleotides (ASO), small interfering RNAs (siRNA), and novel genome editing techniques.Genetic studies have identified potential therapeutic targets that are suggested to play a causative role in development and progression of CVD. RNA- and DNA-targeted therapeutics can be particularly well delivered to the liver, where atherogenic lipoproteins and angiotensinogen (AGT) are produced. Current targets in lipid metabolism include proprotein convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein A (ApoA), apolipoprotein C3 (ApoC3), angiopoietin-like 3 (ANGPTL3). Several large-scale clinical development programs for nucleic acid-targeted therapies in cardiovascular prevention are under way, which may also be attractive from a therapy adherence point of view, given the long action of these therapeutics. In addition to genome editing, the concept of gene transfer is presently under assessment in preclinical and clinical investigations as a potential approach for addressing low-density lipoprotein receptor deficiency. Furthermore, ongoing research is exploring the use of RNA-targeted therapies to treat arterial hypertension by reducing hepatic angiotensinogen (AGT) production.This review summarizes the rapid translation of siRNA and ASO therapeutics as well as gene editing into clinical studies to treat dyslipidemia and arterial hypertension for CVD prevention. It also outlines potential innovative therapeutic options that are likely relevant to the future of cardiovascular medicine.

01 Dec 2021·Journal of Translational MedicineQ2 · MEDICINE

Multi-omic signatures of atherogenic dyslipidaemia: pre-clinical target identification and validation in humans

Q2 · MEDICINE

ArticleOA

Author: Smolenski, Ryszard T ; Debski, Janusz ; Kochan, Zdzislaw ; Olkowicz, Mariola ; Chlopicki, Stefan ; Dadlez, Michal ; Czyzynska-Cichon, Izabela ; Kostogrys, Renata B ; Szupryczynska, Natalia

AbstractBackgroundDyslipidaemia is a major risk factor for atherosclerosis and cardiovascular diseases. The molecular mechanisms that translate dyslipidaemia into atherogenesis and reliable markers of its progression are yet to be fully elucidated. To address this issue, we conducted a comprehensive metabolomic and proteomic analysis in an experimental model of dyslipidaemia and in patients with familial hypercholesterolemia (FH).MethodsLiquid chromatography/mass spectrometry (LC/MS) and immunoassays were used to find out blood alterations at metabolite and protein levels in dyslipidaemic ApoE−/−/LDLR−/− mice and in FH patients to evaluate their human relevance.ResultsWe identified 15 metabolites (inhibitors and substrates of nitric oxide synthase (NOS), low-molecular-weight antioxidants (glutamine, taurine), homocysteine, methionine, 1-methylnicotinamide, alanine and hydroxyproline) and 9 proteins (C-reactive protein, proprotein convertase subtilisin/kexin type 9, apolipoprotein C-III, soluble intercellular adhesion molecule-1, angiotensinogen, paraoxonase-1, fetuin-B, vitamin K-dependent protein S and biglycan) that differentiated FH patients from healthy controls. Most of these changes were consistently found in dyslipidaemic mice and were further amplified if mice were fed an atherogenic (Western or low-carbohydrate, high-protein) diet.ConclusionsThe alterations highlighted the involvement of an immune-inflammatory response system, oxidative stress, hyper-coagulation and impairment in the vascular function/regenerative capacity in response to dyslipidaemia that may also be directly engaged in development of atherosclerosis. Our study further identified potential biomarkers for an increased risk of atherosclerosis that may aid in clinical diagnosis or in the personalized treatment.

Analysis

Perform a panoramic analysis of this field.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis